Infectious Diseases

Infectious-Disease-Petri-dish

WHY FOCUS ON INFECTIOUS DISEASES IN OHIO?

  • Infectious diseases represent the greatest proportion of new diseases discovered in the past 35 years
  • Globally, emerging and re-emerging infections continue to be reported (e.g. MERS Co-V, multi-drug resistant infections, HIV infection, tuberculosis, malaria)
  • There remains the threat of worldwide pandemics of infections (e.g. 2009 pandemic H1N1 influenza)
  • There is already strong clinical research infectious diseases activities and investigators at the major academic institutions in Ohio

Additional opportunities

  • Access the innovation of infectious diseases clinicians and researchers state-wide
  • Leverage outstanding infectious diseases, microbiology and biodefense research laboratories at the major academic institutions in Ohio
  • Enhance interactions with Ohio public health institutions and authorities
  • Facilitated multi-site scientific review
  • Concierge IRB process
  • Access to NIH,DOD, industry and foundation protocols/studies

Establishment of a state-wide research team in infectious diseases via the OCTC

  • Multi-disciplinary team
  • Multi-institutional novel clinical trials in relevant and contemporary areas
  • Utilization of basic and translational capabilities to enhance clinical trials in infectious diseases
  • Opportunities to assess biomarkers in infectious diseases
  • Infectious diseases working group through the OCTC
  • Study conduct at all 3 sites for NIH BARDA, industry protocols
  • Establishment of a clinical database linked to a biorepository
  • Conduct of outcomes and implementation research
Petri-dish-Infectious-Disease-2

Examples of current infectious diseases phase 1 clinical trials in Ohio

  • A phase 1, open-label study of the safety, tolerability and pharmacokinetics of aerosolized colistimethate sodium after multiple doses administered separately or in combination with intravenous colistimethate in healthy adults
  • A phase 1 open-label trial to investigate the pharmacokinetic interaction between rifabutin or rifampin and a single dose of bedaquiline in healthy subjects
  • A two-part phase 1 study to establish and compare the safety and local tolerability of two nasal formulations of XF-73 for decolonization of Staphylococcus aureus: A previously investigated 0.5 mg/g viscosified gel formulation versus a modified formulation